Proboxis Bio

Meeting a global need – flexible, scalable vaccines against mosquito-borne flaviviruses

Japanese encephalitis, dengue, Zika, yellow fever and West Nile virus threaten populations worldwide, placing over 4 billion people at risk. Japanese encephalitis causes about 70,000 clinical cases annually, with fatality rates of up to 30% and leaves many survivors with permanent neurological disabilities. Climate change, expanding mosquito ranges and international travel are increasing the spread of these diseases into new regions.

Proboxis Bio is addressing a critical gap in global infectious disease preparedness: the need for flexible, scalable vaccines against mosquito-borne flaviviruses. Its ISVac™ platform uses benign insect-specific viruses to develop and manufacture vaccines against multiple flaviviruses. By replacing the virus’s surface proteins with those of a disease-causing flavivirus, ISVac™ generates vaccine particles that closely resemble the target pathogen but cannot replicate in humans or other vertebrates.

Unlike single-product approaches, ISVac is designed as a reusable platform supporting multiple vaccine candidates through a shared mosquito-cell production system, manufacturing process, analytical framework, and regulatory knowledge base. Proboxis Bio says its, ISVac-JEV, has generated strong neutralising antibody responses and protected mice and pigs against Japanese encephalitis virus (JEV), providing proof-of-concept for the wider platform.

Biointelect Venturer funding for this project supports Proboxis Bio to advance scalable manufacturing and purification processes; strengthen its commercial, regulatory and intellectual property strategy; and establish the company required to advance ISVac™ platform candidates into clinical trials.

If successful, starting with a new vaccine for JEV, Proboxis Bio’s goal is to build an Australian vaccine company capable of developing a pipeline of vaccines against established and emerging flavivirus threats, strengthening sovereign manufacturing capability while contributing to a more resilient national and global health security framework.

  • BV Round 1 Project: Vaccine Production Platform
  • State: QLD
  • Project Lead: A/Prof Jody Peters
  • Project Partners:
    • The University of Queensland
      • School of Chemistry and Molecular Biosciences (SCMB)
      • Uniquest
      • National Biologics Facility (NBF)
  • Biointelect Venturer Funding: $1,500,000

Eri Nishiuchi

Strategic Development and Business Effectiveness

Eri Nishiuchi holds a Bachelor of Business degree from the University of Technology Sydney. Her expertise lies in health systems analysis and client relationship management within the healthcare and life sciences sectors. She also has experience working with patient organisations.

Throughout her career, Eri has provided competitive landscape research support to pharmaceutical and biotech clients across the Asia Pacific region, achieving one of the top client retention rates in the region. Her multilingual abilities have been instrumental in fostering strong relationships with diverse stakeholders.

Eri joined Biointelect in 2024 in a strategic development and business effectiveness role, where her focus will be on conducting market analysis and improving business processes.